加拿大雷珠单抗治疗-延长方案治疗新生血管性年龄相关性黄斑变性的一年随机试验结果
这项前瞻性随机对照非劣效性研究比较了雷珠单抗治疗-延长(T&E)方案与每月给药方案在初治新生血管性年龄相关性黄斑变性(nAMD)患者中的疗效。12个月结果显示,T&E组最佳矫正视力(BCVA)平均提升8.4个字母,每月给药组提升6.0个字母,达到非劣效标准,且T&E组注射次数显著更少(9.4次 vs 11.8次)。
要点
- T&E方案12个月视力改善非劣效于每月给药方案。
- T&E组平均注射9.4次,显著少于每月给药组的11.8次。
- 两组基线特征无显著差异,主要终点为BCVA字母变化。
核心结论
- 雷珠单抗T&E方案在12个月视力结局上非劣效于每月给药方案。
- T&E方案以显著更少的注射次数达到与每月给药相似的视力结局。
研究设计与样本
- 前瞻性、随机、开放标签、多中心、非劣效性、上市后研究。
- 初治nAMD患者按1:1随机接受0.5 mg雷珠单抗T&E或每月给药。
- 非劣效界值为BCVA提升5个字母。
- 共有526例患者提供基线和12个月视力数据(T&E组268例,每月给药组258例)。
- 基线平均年龄78.8岁(标准差7.8岁),女性占60.3%,白人占94.3%。
主要发现
- T&E组BCVA平均提升8.4个字母(标准差11.9),每月给药组提升6.0个字母(标准差11.9),P=0.017。
- 组间平均差异为2.38个字母(95%CI 0.32-4.45)。
- T&E组平均注射9.4次,每月给药组平均注射11.8次,平均差异-2.46次(95%CI -2.68至-2.23)。
关键数值与推荐
- 非劣效性主要终点为第12个月BCVA较基线的平均变化字母数。
- 非劣效界值为5个字母。
- T&E组与每月给药组的BCVA平均提升分别为8.4和6.0个字母,组间差异2.38个字母(95%CI 0.32-4.45)。
- T&E组注射次数显著少于每月给药组(9.4 vs 11.8次,平均差异-2.46次,95%CI -2.68至-2.23)。
临床怎么用
- 对于初治nAMD患者,可考虑采用雷珠单抗T&E方案以减少注射负担。
- T&E方案在12个月时视力改善不劣于每月给药,且注射次数更少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the efficacy of ranibizumab using a treat-and-extend (T&E) regimen with monthly dosing in treatment-naive patients with neovascular age-related macular degeneration (nAMD). DESIGN: Prospective, randomized, open-label, multicenter, noninferiority, postauthorization study. PARTICIPANTS: Treatment-naive patients with choroidal neovascularization secondary to AMD. METHODS: Patients with nAMD were randomized 1:1 to receive intravitreal ranibizumab at a dose of 0.5 mg in either a T&E or monthly dosing regimen. The noninferiority of T&E compared with the monthly dosing regimen was to be shown using a margin of 5 letters in best-corrected visual acuity (BCVA) improvement. MAIN OUTCOME MEASURES: Mean change in BCVA in Early Treatment Diabetic Retinopathy Study letters from baseline to month 12. RESULTS: Baseline and 12-month visual acuity data are available for 526 patients (T&E, n = 268; monthly, n = 258). At baseline, mean age was 78.8 years (standard deviation [SD], 7.8 years), 60.3% were women, and 94.3% were white. No significant between-group baseline differences were observed. The primary outcome of noninferiority regarding visual acuity was met with mean BCVA improvement of 8.4 letters (SD, 11.9 letters) and 6.0 letters (SD, 11.9 letters; P = 0.017) in the T&E and monthly regimens, respectively, with a between-group mean difference of 2.38 letters (95% confidence interval, 0.32-4.45 letters). Per protocol, a secondary analysis was performed to test for superiority of number of injections received up to month 12. This analysis demonstrated significantly fewer injections with T&E versus monthly dosing (9.4 and 11.8 injections, respectively), with a mean difference of -2.46 injections (95% confidence interval, -2.68 to -2.23 injections). CONCLUSIONS: The 12-month results of this 2-year study demonstrated that regarding visual outcomes, the T&E regimen was noninferior to a monthly dosing regimen. Similar visual outcomes in the T&E group as in the monthly dosing group were achieved with significantly fewer injections.
引用
- Kertes PJ, Galic IJ, Greve M, et al. Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study. Ophthalmology. 2019. PMID: 30677465. doi:10.1016/j.ophtha.2019.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。